Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbationsFront Immunol 2023 Sep 01;14(xx)1242508, NL Ciano-Petersen, P Aliaga-Gaspar, I Hurtado-Guerrero, V Reyes, JL Rodriguez-Bada, E Rodriguez-Traver, I Brichette-Mieg, L Leyva Fernández, P Serrano-Castro, A Alonso, B Oliver-Martos
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.